East Windsor, N.J. – Aurobindo Pharma Limited has launched Atazanavir Capsules 100 mg, 150 mg, 200 mg, and 300 mg upon receiving final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Aurobindo’s Atazanavir Capsules are an AB-rated generic equivalent to the reference listed drug REYATAZ®.

Atazanavir capsules is indicated for use in combination with other antiretroviral agents for the treatment of HIV infection.

Atazanavir capsules represent the latest addition to Aurobindo’s broad line of vertically integrated generic pharmaceuticals. Aurobindo’s product portfolio consists of 371 final approvals, including 32 tentative approvals, and 17 approved products from Aurolife. There are 113 additional products on file with U.S. FDA.

The product has an estimated market size of $324.4M for the twelve months ending April 2018 according to IQVIA*.